

Supplementary Appendix

Cefiderocol protects against cytokine- and endotoxin-induced disruption of vascular endothelial cell integrity in an *in vitro* experimental model.

Supplementary Method

PBMCs were treated with anti CD3/CD28-coated activation beads (Miltenyi Biotech, Bergisch Gladbach, Germany) in a ratio of 1 (cells):10 (beads) +/- cefiderocol (10mg/L, 40mg/L, 70mg/L) for 3 days. Then, cells were stained with 5µl/ 100.000 cells Annexin-FITC (Thermo Fisher Scientific, Walldorf, Germany) for 15 min at rt and subsequently analyzed on a FACSCanto (Becton Dickinson, Heidelberg, Germany).

Supplementary Figure S1. Cefiderocol does not significantly decrease PBMC viability.

PBMCs were treated with cefiderocol (FDC 10 mg/L, 40 mg/L, 70 mg/L) for 3 days or left unstimulated. Cells were stained with Annexin-FITC and analyzed on a FACSCanto for percentage of Annexin-positive apoptotic cells. Shown is mean and standard deviation of n=4. Statistical significance was calculated using a one-sided Mann-Whitney U test. There was no statistical significance. Abbreviations: FDC= cefiderocol.

